$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Avadel Pharmaceuticals plc (NASDAQ: AVDL)

Core Viewpoint - Monteverde & Associates PC is investigating Avadel Pharmaceuticals plc regarding its proposed sale to Alkermes plc, which includes a cash payment of $18.50 per share and a contingent value right of $1.50 per share, pending FDA approval of LUMRYZ™ by the end of 2028 [1]. Group 1: Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has recovered millions for shareholders [1]. - The firm is headquartered in the Empire State Building, New York City, and specializes in class action securities litigation [2]. Group 2: Transaction Details - Avadel shareholders are set to receive $18.50 per share in the proposed transaction with Alkermes plc [1]. - Additionally, shareholders may receive a contingent payment of $1.50 per share, contingent upon the FDA's final approval of LUMRYZ™ for treating idiopathic hypersomnia by the end of 2028 [1].